PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22117063-4 2012 This reparative phenotype in Vim(-/-) corneas is strikingly recapitulated by the pharmacological agent withaferin A (WFA), a small molecule that binds to vimentin and down-regulates its injury-induced expression. withaferin A 103-115 vimentin Mus musculus 29-32 31336025-0 2019 Withaferin A reverses bile duct ligation-induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2/Snail1, vimentin, and NFkappaB signaling. withaferin A 0-12 vimentin Mus musculus 133-141 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 29-41 vimentin Mus musculus 65-73 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 29-41 vimentin Mus musculus 148-156 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 29-41 vimentin Mus musculus 148-156 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 43-46 vimentin Mus musculus 65-73 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 43-46 vimentin Mus musculus 148-156 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 43-46 vimentin Mus musculus 148-156 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 88-91 vimentin Mus musculus 65-73 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 88-91 vimentin Mus musculus 148-156 30590024-6 2019 Employing the small molecule withaferin A (WFA), an inhibitor of vimentin, we show that WFA treatment causes the decrease in steady state levels of vimentin and serine 38 phosphorylated vimentin, the latter a biomarker associated with corneal fibrosis, and improved corneal clarity through blockade of myofibroblast differentiation. withaferin A 88-91 vimentin Mus musculus 148-156 26186445-0 2015 Vimentin Phosphorylation Underlies Myofibroblast Sensitivity to Withaferin A In Vitro and during Corneal Fibrosis. withaferin A 64-76 vimentin Mus musculus 0-8 26186445-4 2015 Moreover, the soluble vimentin-targeting small molecule and fibrotic inhibitor withaferin A (WFA) causes a potent blockade of cell spreading selectively in myofibroblasts by targeting soluble pSer38Vim for hyperphosphorylation. withaferin A 79-91 vimentin Mus musculus 22-30 26186445-4 2015 Moreover, the soluble vimentin-targeting small molecule and fibrotic inhibitor withaferin A (WFA) causes a potent blockade of cell spreading selectively in myofibroblasts by targeting soluble pSer38Vim for hyperphosphorylation. withaferin A 93-96 vimentin Mus musculus 22-30 22117063-4 2012 This reparative phenotype in Vim(-/-) corneas is strikingly recapitulated by the pharmacological agent withaferin A (WFA), a small molecule that binds to vimentin and down-regulates its injury-induced expression. withaferin A 103-115 vimentin Mus musculus 154-162 22117063-4 2012 This reparative phenotype in Vim(-/-) corneas is strikingly recapitulated by the pharmacological agent withaferin A (WFA), a small molecule that binds to vimentin and down-regulates its injury-induced expression. withaferin A 117-120 vimentin Mus musculus 29-32 22117063-4 2012 This reparative phenotype in Vim(-/-) corneas is strikingly recapitulated by the pharmacological agent withaferin A (WFA), a small molecule that binds to vimentin and down-regulates its injury-induced expression. withaferin A 117-120 vimentin Mus musculus 154-162 20419128-3 2010 Withaferin-A, a naturally derived bioactive compound, may molecularly target vimentin, so we sought to evaluate its effects on tumor growth in vitro and in vivo thereby elucidating the role of vimentin in drug-induced responses. withaferin A 0-12 vimentin Mus musculus 77-85 21538350-0 2011 Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. withaferin A 0-12 vimentin Mus musculus 95-103 21538350-1 2011 Withaferin A (WFA) is purified from the plant Withania somnifera and inhibits the vimentin cytoskeleton. withaferin A 0-12 vimentin Mus musculus 82-90 21538350-1 2011 Withaferin A (WFA) is purified from the plant Withania somnifera and inhibits the vimentin cytoskeleton. withaferin A 14-17 vimentin Mus musculus 82-90 21538350-5 2011 Imaging of breast cancer cell lines revealed that WFA induces perinuclear vimentin accumulation followed by rapid vimentin depolymerization. withaferin A 50-53 vimentin Mus musculus 74-82 21538350-5 2011 Imaging of breast cancer cell lines revealed that WFA induces perinuclear vimentin accumulation followed by rapid vimentin depolymerization. withaferin A 50-53 vimentin Mus musculus 114-122 21538350-9 2011 In a breast cancer metastasis mouse model, WFA showed dose-dependent inhibition of metastatic lung nodules and induced vimentin ser56 phosphorylation, with minimal toxicity to lung tissue. withaferin A 43-46 vimentin Mus musculus 119-127 21538350-10 2011 Based upon these studies, we conclude that WFA is a potent breast cancer anti-metastatic agent and the anti-metastatic activity of WFA is, at least in part, mediated through its effects on vimentin and vimentin ser56 phosphorylation. withaferin A 43-46 vimentin Mus musculus 189-197 21538350-10 2011 Based upon these studies, we conclude that WFA is a potent breast cancer anti-metastatic agent and the anti-metastatic activity of WFA is, at least in part, mediated through its effects on vimentin and vimentin ser56 phosphorylation. withaferin A 43-46 vimentin Mus musculus 202-210 21538350-10 2011 Based upon these studies, we conclude that WFA is a potent breast cancer anti-metastatic agent and the anti-metastatic activity of WFA is, at least in part, mediated through its effects on vimentin and vimentin ser56 phosphorylation. withaferin A 131-134 vimentin Mus musculus 189-197 21538350-10 2011 Based upon these studies, we conclude that WFA is a potent breast cancer anti-metastatic agent and the anti-metastatic activity of WFA is, at least in part, mediated through its effects on vimentin and vimentin ser56 phosphorylation. withaferin A 131-134 vimentin Mus musculus 202-210 20419128-3 2010 Withaferin-A, a naturally derived bioactive compound, may molecularly target vimentin, so we sought to evaluate its effects on tumor growth in vitro and in vivo thereby elucidating the role of vimentin in drug-induced responses. withaferin A 0-12 vimentin Mus musculus 193-201 20419128-4 2010 METHODS AND FINDINGS: Withaferin-A elicited marked apoptosis and vimentin cleavage in vimentin-expressing tumor cells but significantly less in normal mesenchymal cells. withaferin A 22-34 vimentin Mus musculus 65-73 20419128-4 2010 METHODS AND FINDINGS: Withaferin-A elicited marked apoptosis and vimentin cleavage in vimentin-expressing tumor cells but significantly less in normal mesenchymal cells. withaferin A 22-34 vimentin Mus musculus 86-94 20419128-8 2010 Apoptosis, decreased angiogenesis, and vimentin degradation were all seen in Withaferin-A treated specimens. withaferin A 77-89 vimentin Mus musculus 39-47 20048155-0 2010 Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. withaferin A 0-12 vimentin Mus musculus 80-88 20048155-3 2010 Here, we demonstrate that the vimentin-targeting small molecule withaferin A (WFA) is a novel chemical probe of GFAP. withaferin A 64-76 vimentin Mus musculus 30-38 20048155-3 2010 Here, we demonstrate that the vimentin-targeting small molecule withaferin A (WFA) is a novel chemical probe of GFAP. withaferin A 78-81 vimentin Mus musculus 30-38 20048155-4 2010 Using molecular modeling studies that build on the x-ray crystal structure of tetrameric vimentin rod 2B domain we reveal that the WFA binding site is conserved in the corresponding domain of tetrameric GFAP. withaferin A 131-134 vimentin Mus musculus 89-97 17584610-0 2007 The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. withaferin A 45-57 vimentin Mus musculus 100-108 17584610-2 2007 Here, we show that WFA binds to the intermediate filament (IF) protein, vimentin, by covalently modifying its cysteine residue, which is present in the highly conserved alpha-helical coiled coil 2B domain. withaferin A 19-22 vimentin Mus musculus 72-80 17584610-3 2007 WFA induces vimentin filaments to aggregate in vitro, an activity manifested in vivo as punctate cytoplasmic aggregates that colocalize vimentin and F-actin. withaferin A 0-3 vimentin Mus musculus 12-20 17584610-3 2007 WFA induces vimentin filaments to aggregate in vitro, an activity manifested in vivo as punctate cytoplasmic aggregates that colocalize vimentin and F-actin. withaferin A 0-3 vimentin Mus musculus 136-144 17584610-5 2007 Finally, we show that WFA-induced inhibition of capillary growth in a mouse model of corneal neovascularization is compromised in vimentin-deficient mice. withaferin A 22-25 vimentin Mus musculus 130-138